U.S. Markets closed
  • S&P 500

    4,397.94
    -84.79 (-1.89%)
     
  • Dow 30

    34,265.37
    -450.03 (-1.30%)
     
  • Nasdaq

    13,768.92
    -385.08 (-2.72%)
     
  • Russell 2000

    1,987.92
    -36.12 (-1.78%)
     
  • Crude Oil

    84.81
    -0.74 (-0.86%)
     
  • Gold

    1,836.10
    -6.50 (-0.35%)
     
  • Silver

    24.34
    -0.37 (-1.50%)
     
  • EUR/USD

    1.1355
    +0.0037 (+0.3293%)
     
  • 10-Yr Bond

    1.7470
    -0.0860 (-4.69%)
     
  • Vix

    28.85
    +3.26 (+12.74%)
     
  • GBP/USD

    1.3546
    -0.0055 (-0.4010%)
     
  • USD/JPY

    113.6550
    -0.4450 (-0.3900%)
     
  • BTC-USD

    36,821.89
    -4,602.85 (-11.11%)
     
  • CMC Crypto 200

    870.86
    +628.18 (+258.85%)
     
  • FTSE 100

    7,494.13
    -90.88 (-1.20%)
     
  • Nikkei 225

    27,522.26
    -250.64 (-0.90%)
     

Baidu Licenses Its Algorithm To Sanofi For mRNA Vaccine, Therapy Development

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • BIDU
  • SNY

Baidu Inc (NASDAQ: BIDU) has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA (NASDAQ: SNY) for use in designing vaccine and therapeutic products. The deal marks Baidu's first such commercial deal with a major global drugmaker.

  • Also Read: Sanofi Stops Work On Its mRNA COVID-19 Vaccine: What You Need To Know.

  • Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.

  • "The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market," Huang told Reuters. He declined to disclose the size of the deal.

  • LinearDesign is a novel algorithm developed by Baidu researchers in 2020 specifically for mRNA sequence design.

  • Experiments both in vitro and in vivo have demonstrated the effectiveness of LinearDesign in improving the stability and immunogenicity of Spike protein-encoding mRNA.

  • Price Action: BIDU shares are down 0.86% at $150.47, SNY shares are down 0.87% at $50.19 during the market session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.